Nossent H C, Koldingsnes W
Department of Rheumatology, University Hospital Tromsø, Norway.
Rheumatology (Oxford). 2000 Sep;39(9):969-74. doi: 10.1093/rheumatology/39.9.969.
Combination therapy with cytotoxic drugs and corticosteroids reduces the risk for renal failure in patients with proliferative lupus nephritis (PLN), but uncertainty remains about the best mode of immunosuppression and its long-term effects. We report long-term results of combined azathioprine-prednisolone treatment for PLN, which has been the therapy of choice for the treatment of PLN at our centre for 15 yr.
A retrospective cohort study was carried out of 26 lupus patients, seen between 1978 and 1993, with histological and/or clinical evidence of PLN. Therapy consisted of prednisolone 1 mg/kg daily, tapered after 4 weeks to the lowest possible maintenance dose combined with azathioprine up to 2.5 mg/kg. Median duration of azathioprine treatment was 53 months. Standard statistical lifetable analyses were performed.
Median follow-up on 1 January 1998 was 119 months. Patient survival estimates after 5, 10 and 15 yr of follow-up were 96, 91 and 82%, respectively. Four patients (15%) developed end-stage renal failure and three received renal transplants after a mean period of 27 months on haemodialysis. Renal survival estimates after 5, 10 and 15 yr of follow-up were 92, 87 and 87%, respectively. No malignancies were seen during the study period.
Azathioprine treatment for 4-1/2 yr was well tolerated in this cohort of Caucasian patients with PLN and was associated with outcomes similar to those reported for pulse cyclophosphamide therapy.
细胞毒性药物与皮质类固醇联合治疗可降低增殖性狼疮性肾炎(PLN)患者肾衰竭的风险,但免疫抑制的最佳模式及其长期影响仍不确定。我们报告了硫唑嘌呤 - 泼尼松龙联合治疗PLN的长期结果,在我们中心,这是15年来治疗PLN的首选疗法。
对1978年至1993年间就诊的26例狼疮患者进行了一项回顾性队列研究,这些患者有PLN的组织学和/或临床证据。治疗方案为每日口服泼尼松龙1mg/kg,4周后逐渐减量至最低维持剂量,并联合使用硫唑嘌呤,剂量最高可达2.5mg/kg。硫唑嘌呤治疗的中位持续时间为53个月。进行了标准的统计生命表分析。
1998年1月1日的中位随访时间为119个月。随访5年、10年和15年的患者生存率估计分别为96%、91%和82%。4例患者(15%)发展为终末期肾衰竭,3例在平均27个月的血液透析后接受了肾移植。随访5年、10年和15年的肾脏生存率估计分别为92%、87%和87%。研究期间未发现恶性肿瘤。
在这组患有PLN的白种人患者中,4年半的硫唑嘌呤治疗耐受性良好,其结果与脉冲环磷酰胺治疗报告的结果相似。